These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29218901)

  • 1. Using simulation and optimization approach to improve outcome through warfarin precision treatment.
    Chi CL; He L; Ravvaz K; Weissert J; Tonellato PJ
    Pac Symp Biocomput; 2018; 23():412-423. PubMed ID: 29218901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal decision support rules improve personalize warfarin treatment outcomes.
    Chih-Lin Chi ; Ravvaz K; Weissert J; Tonellato PJ
    Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2594-2597. PubMed ID: 28268853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.
    Ravvaz K; Weissert JA; Ruff CT; Chi CL; Tonellato PJ
    Circ Cardiovasc Genet; 2017 Dec; 10(6):. PubMed ID: 29237680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-guided warfarin therapy: current status.
    Tavares LC; Marcatto LR; Santos PCJL
    Pharmacogenomics; 2018 May; 19(7):667-685. PubMed ID: 29701078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of adequate use of warfarin for the elderly using decision tree-based approaches.
    Liu KE; Lo CL; Hu YH
    Methods Inf Med; 2014; 53(1):47-53. PubMed ID: 24136011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
    Robertson SL; Mayer JB; Guthmann R
    J Fam Pract; 2004 Jul; 53(7):570-5. PubMed ID: 15251100
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?
    Eckman MH; Wong LK; Soo YO; Lam W; Yang SR; Greenberg SM; Rosand J
    Stroke; 2008 Dec; 39(12):3308-15. PubMed ID: 18845797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
    Mendoza-Sanchez J; Silva F; Rangel L; Jaramillo L; Mendoza L; Garzon J; Quiroga A
    PLoS One; 2018; 13(5):e0196361. PubMed ID: 29723207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.
    Pandya EY; Bajorek B
    Patient; 2017 Apr; 10(2):163-185. PubMed ID: 27438598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring.
    Simmons BJ; Jenner KM; Delate T; Clark NP; Kurz D; Witt DM
    Pharmacotherapy; 2012 Dec; 32(12):1078-84. PubMed ID: 23112110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency department management of patients on warfarin therapy.
    Meeker E; Dennehy CE; Weber EJ; Kayser SR
    Ann Emerg Med; 2011 Aug; 58(2):192-9. PubMed ID: 21481971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation.
    Kaiser K; Cheng WY; Jensen S; Clayman ML; Thappa A; Schwiep F; Chawla A; Goldberger JJ; Col N; Schein J
    Curr Med Res Opin; 2015 Dec; 31(12):2261-72. PubMed ID: 26390360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption.
    Nutescu EA; Bathija S; Sharp LK; Gerber BS; Schumock GT; Fitzgibbon ML
    Pharmacotherapy; 2011 Dec; 31(12):1161-74. PubMed ID: 22122179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Aid Tool to Improve Decision Making in Anticoagulation for Stroke Prevention.
    Saposnik G; Joundi RA
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2380-5. PubMed ID: 27318647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the management of patients with head injury taking warfarin: who should we scan and when? Lessons from the AHEAD study.
    Mason SM; Evans R; Kuczawski M
    Emerg Med J; 2019 Jan; 36(1):47-51. PubMed ID: 30065073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol.
    Li G; Holbrook A; Delate T; Witt DM; Levine MA; Thabane L
    BMJ Open; 2015 Nov; 5(11):e009518. PubMed ID: 26546146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis.
    Gerson LB; Triadafilopoulos G; Gage BF
    Am J Med; 2004 Apr; 116(7):451-9. PubMed ID: 15047034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.